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Background: Psoriasis is a chronic inﬂammatory disease affecting the quality of life of patients. Traditional
treatments are limited by adverse side effects. Etanercept is a biological agent used as an alternative
treatment for psoriasis.
Methods: This open-label, observational study conducted in Taiwan involved 22 patients with recalcitrant
psoriasis who received a 24-week treatment with etanerceptd50 mg twice weekly (BIW) during the ﬁrst
12 weeks and 25 mg BIW in the next 12 weeks. Psoriasis Area and Severity Index (PASI) score at Weeks 0,
12, and 24 were recorded. Levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP),
antinuclear antibody (ANA), and tumor necrosis factor-alpha (TNF-a) at baseline, Week 12, and Week 24
were obtained. Adverse events and blood tests were recorded as safety assessment.
Results: At Week 12, 54.5% and 13.6% patients achieved 50% improvement from baseline in PASI score
(PASI 50 and PASI 75, respectively); at Week 24, 66.7% and 23.8% patients achieved PASI 50 and PASI 75,
respectively. The mean improvement in PASI was 49.8% at Week 12 and 59.8% at Week 24, while 100%
and 62.5% patients had reduced ESR and CRP levels, respectively. There were no deaths or serious adverse
events. Four patients developed positive ANA, one of whom had poor psoriasis control. Most patients
(93.8%) had higher serum TNF-a levels compared to baseline.
Conclusions: Etanercept is effective and safe in treating recalcitrant psoriasis, reduces ESR and CRP levels,
and occasionally induces positive ANA titer associated with poor psoriasis control. Serum TNF-a level
may increase after treatment, but this does not seem to affect PASI improvement.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Psoriasis is a chronic inﬂammatory dermatological disorder that
impairs the quality of life of patients both physically and psycho-
logically. Its prevalence is estimated to be 2%,1 and the total rate of
psoriasis in children younger than 18 years old, including about
3.5e16% infantile patients,2 has been reported to be 0.71%.3 In
Taiwan, the mean 1-year prevalence rate is about 0.19%.4 Tradi-
tional therapies such as retinoids, methotrexate, and cyclosporine,
sometimes combined with phototherapy, have been in use for
a long time, but therapeutic limitations, including elevated liver
function and lipid proﬁles in retinoids, hypertension and impairedogy, Chang Gung Memorial
wan. Tel.: þ886 2 27135211
H. Huang).
iwanese Dermatological Associatiorenal function in cyclosporine, and liver toxicity in methotrexate,
still exist. Moreover, some patients do not respond well to these
regimens.
Biological agents, such as tumor necrosis factor (TNF) antago-
nists, have been developed as alternative treatments for psoriasis.
Currently available TNF antagonists include inﬂiximab, etanercept,
and adalimumab.5 Etanercept, a human fusion protein, binds to the
TNF receptor and inhibits the cascade of the inﬂammatory process.
It has been approved as a treatment for moderate-to-severe plaque
psoriasis in the United States and the European Union.5 In Taiwan,
etanercept is used as a second-line treatment for patients with
chronic, moderate-to-severe plaque or palmoplantar psoriasis.
Previous clinical trials have elucidated that etanercept is effective
and safe in treating patients with moderate-to-severe psoriasis.6e8
There are also published open-label, observational studies showing
satisfactory Psoriasis Area and Severity Index (PASI) reduction
using etanercept in patients with moderate-to-severe psoriasis in
clinical practice.9,10n. Published by Elsevier Taiwan LLC. All rights reserved.
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tory markers of psoriasis, such as erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP).11,12 A retrospective study has
shown the role of antinuclear antibody (ANA) as a marker for
treatment failure in TNF antagonists.13 Elevated serum TNF-a levels
after using etanercept to treat diseases other than psoriasis has
previously been reported.14e17
This is an open-label, observational, retrospective analysis of the
efﬁcacy and safety of etanercept in Asian clinical practice to treat
recalcitrant psoriasis patients, namely those who were contra-
indicated to or failed to improve with at least two traditional
regimens plus phototherapy. Relationships between treatment
response, and elevated ANA titer and higher serum TNF-a level are
also discussed.Materials and methods
Patients
Between August 2009 andMarch 2012, 22 Taiwanese adult patients
(15 men and seven women; mean age 36.6 years, range 21e70
years) with chronic plaque psoriasis (mean duration 14.8 years,
range 6e37 years) were enrolled in the study. Their baseline
characteristics are listed in Table 1. All patients received photo-
therapy, and 21 received more than two systemic agents for at least
3months. One patient was not suitable for traditional regimens due
to uncontrolled hypertension, abnormal liver function, and high
lipid proﬁle. The body surface area remained >10% and the PASI
scores >10 in all patients despite traditional treatments.Treatment protocol
The evaluation period was 24 weeks. All patients received subcu-
taneous injections of etanercept 50 mg twice a week (BIW) during
the ﬁrst 12 weeks, followed by 25 mg BIW in the next 12 weeks. No
concomitant systemic treatment or phototherapy was used. Eight
(36.4%) patients did not receive topical medications (topical steroid,
coal tar, or vitamin D3 analogs), while 14 (63.6%) received
concomitant topical medications.Table 1 Baseline demographics and characteristics of the study group.
Characteristics n ¼ 22
Age, y (range) 36.6 (21e70)
Gender
Female, n (%) 7 (31.8)
Male, n (%) 15 (68.2)
Mean weight, kg (range) 73.7 (46e110)
BMI, mean (range) 27.0 (19.4e44.62)
Duration of psoriasis, y, mean (range) 14.8 (5e34)
PASI, mean (range) 24.0 (11.8e42.7)
Associated with psoriatic arthritis, n (%) 6 (27.3)
Psoriasis treatment history
2 systemic treatments, n (%) 21 (95.5)
Phototherapy, n (%) 22 (100.0)
Concomitant treatment with topical medication 14 (63.6)
CRP 5 mg/L, n (%) 8 (36.4)
ESR 15 mm/h, n (%) 4 (18.1)
Positive result in QFT-G test 0 (0.0)
Suspicious TB in chest X-ray 0 (0.0)
HBV carrier, n (%) 1 (4.5)
BMI ¼ body mass index; CRP ¼ C-reactive protein; ESR ¼ erythrocyte sedimen-
tation rate; HBV ¼ hepatitis B virus; PASI ¼ Psoriasis Area and Severity Index;
QFT-G ¼ QuantiFERON-TB Gold; TB ¼ tuberculosis.Efﬁcacy assessment
Evaluation of efﬁcacy included PASI score and laboratory data. At
baseline and Weeks 12 and 24, PASI scores and results of blood
tests, including ESR, CRP, ANA, TNF-a, were collected. The mean
improvement and improvement in PASI scores of 25%, 50%,
75%, and 90% (deﬁned as PASI 25, PASI 50, PASI 75, and PASI 90,
respectively) were also assessed.
Safety assessment
Prior to etanercept injection, all patients had received
QuantiFERON-TB Gold (QFT-G) test and chest X-ray examination.
Neither any positive QFT-G test nor any suspicious tuberculosis
infection on chest X-ray was found prior to treatment. All patients
received a follow-up of chest X-ray 6months later. During the study
period, blood tests including complete blood cell count with
differential count and liver function tests were performed every
month. One patient with hepatitis B virus (HBV) infection under-
went serum viral load examination prior to treatment and at Week
24. Adverse events of etanercept treatment were assessed in all
patients during each clinical visit.
Statistical analysis
The ManneWhitney test was used to compare the PASI improve-
ment between patients treated with and without concomitant
topical medications and between those with and without concur-
rent psoriatic arthritis (PsA). All analyzed results were considered
statistically signiﬁcant at p < 0.05. The relationship between the
increment of serum TNF-a level and the PASI improvement was
evaluated using linear regression analysis.
Results
Efﬁcacy
The mean PASI score and PASI improvement (%) at baseline and
Weeks 12 and 24 are listed in Table 2. All patients completed the 12-
week data collection, while 21 of 22 patients completed the 24-
week treatment course. One patient withdrew from the study
after Week 12 due to poor compliance. No laboratory data were
obtained at Week 12 or 24 for this patient. The mean PASI
improvement rate at Week 12 was 49.8%. By Week 24, the mean
PASI improvement was 59.8% (Table 2). At Week 12, 19 (86.3%), 12
(54.5%), three (13.6%), and one (4.5%) patient achieved PASI 25, PASI
50, PASI 75, and PASI 90, respectively. At Week 24, 20 (95.2%),
14(66.7%), ﬁve (23.8%), and three (14.3%) patients achieved PASI 25,
PASI 50, PASI 75, and PASI 90, respectively (Figure 1). As the
treatment period extended, more patients achieved PASI responses.
Six (27.3%) patients had concurrent psoriasis and PsA. The PASI
improvement in patients with PsAwas 50.8% at Week 12 and 70.0%Table 2 PASI score, PASI improvement, and the number of patients with laboratory
data changes at baseline and Weeks 12 and 24.
Baseline Week 12 Week 24
PASI, mean  SD 24.0  8.5 11.8  7.2 8.9  5.0
PASI improvement, % d 49.8 59.8
ESR reduction, n (%) d 4/4 (100) 4/4 (100)
CRP reduction, n (%) d 8/8 (100) 5/8 (62.5)
ANA development, n (%) d 2/22 (9.1) 4/22 (18.2)
Elevation of TNF-a level, n (%) d 15/16 (93.8) d
ANA ¼ antinuclear antibody; CRP ¼ C-reactive protein; ESR ¼ erythrocyte sedi-
mentation rate; PASI ¼ Psoriasis Area and Severity Index; TNF-a ¼ tumor necrosis
factor-alpha.
Figure 1 Response rates in patients achieving 25% improvement from baseline in
PASI 25, PASI 50, PASI 75, and PASI 90 scores at Weeks 12 and 24. PASI ¼ Psoriasis Area
and Severity Index.
Table 4 Comparison of the mean PASI improvement between patients with and
without PsA.
Mean PASI improvement (%)
at Week 12
PASI improvement
(%) at Week 24
(A) With PsA (n ¼ 6), % 50.8 70.0
(B) Without PsA (n ¼ 16), % 49.4 56.6
(C) Total (n ¼ 22), % 49.8 59.8
Value of p for (A) and (B)* 0.94 0.91
* Signiﬁcant at p < 0.05.
PASI ¼ Psoriasis Area and Severity Index; PsA ¼ psoriatic arthritis.
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between patients with and without PsA did not show statistical
signiﬁcance (p ¼ 0.94 and 0.90 at Week 12 and Week 24,
respectively).
PASI improvements (%) at Weeks 12 and 24 in patients treated
with and without concomitant topical medications are listed in
Table 4. Patients treated without topical medications had better
psoriasis control at both Week 12 (p ¼ 0.0002) and Week 24
(p < 0.0001).Safety
During the 24-week period, 10 (45.4%) patients had upper respi-
ratory infection. One patient (4.5%) complained of chest tightness,
while two (9.1%) had elevated liver function more than twice the
upper normal limit. The patient with HBV infection had neither
abnormal liver function nor increased viral load. There was no
death, malignancy, serious infection, demyelinating disorder, or
hematologic abnormality.Laboratory data
Four (18.1%) patients had elevated ESR level (15 mm/h) at base-
line. At Week 12, all four (100.0%) patients had reduced ESR levels,
which they maintained until Week 24 (Table 2).
Eight (36.4%) patients had elevated CRP level (5 mg/L) at
baseline. ByWeek 12, all of them (100%) had reduced CRP levels. By
Week 24, ﬁve of the eight (62.5%) patients maintained the reduc-
tion in CRP levels, while three (37.5%) had higher CRP levels than
baseline.
Four (18.2%) patients developed positive ANA titers at Week 24.
Three of them (75.0%) achieved PASI improvement of >66%, while
one (25.0%) had poorer psoriasis control. The PASI improvement inTable 3 Comparison of the response rates (%) in achievement of25% improvement from
two etanercept studies conducted in Taiwan.
Week 12
PASI 25 PASI 50 PASI 75
Present study (n ¼ 22), % 86.3 54.5 13.6
Chiu et al10 (n ¼ 59), % d 48 26
PASI ¼ Psoriasis Area and Severity Index.this patient was 15.3% and 11.9% at Week 12 and Week 24,
respectively.
Serum TNF-a levels were monitored in 16 (72.7%) patients
(mean 26.4 pg/mL, range 6.7e175 pg/mL) at baseline and Week 12.
Fifteen of the 16 (93.8%) had elevated TNF-a levels (mean 137.9 pg/
mL, range 61e270 pg/mL) after treatment, while one (8.3%) had
reduced TNF-a level (from 175 to 79.1 pg/mL). By Week 12, the
mean PASI improvement in patients with elevated TNF-a level was
46.8%. Elevation rate (%) and PASI improvement (%) were not
correlated (R2 ¼ 0.096 and p ¼ 0.72).Discussion
This study demonstrates the efﬁcacy and safety of etanercept in the
treatment of refractory psoriasis in Taiwanese clinical practice. The
dosage of etanercept was 50 mg BIW in the ﬁrst 12 weeks, which
tapered to 25 mg BIW in the next 12 weeks, following the treat-
ment guidelines recommended by Menter et al.1 The evaluation
period was 24 weeks. The results of the present study showed the
response rates of PASI 50, PASI 75, and PASI 90 to be 54.5%, 13.6%,
and 4.5%, respectively, at Week 12. One double-blind, placebo-
controlled, randomized phase III trial with the same dosage of
etanercept had response rates of PASI 50, PASI 75, and PASI 90 as
74%, 47%, and 21% at Week 12, respectively.6
An open-label study in Greece that used the same dosage of
etanercept to treat patients with moderate-to-severe psoriasis
revealed that 46.3% patients achieved PASI 75 by Week 12.11
Another case series study in Taiwan showed that, at Week 12, no
statistical signiﬁcance was noted in PASI improvement between
two groups treated with 50 and 25 mg BIW separately (40.8% vs.
49.4%, p ¼ 0.41).10 In this study, 48%, 26%, and 3% of patients ach-
ieved PASI 50, PASI 75, and PASI 90, respectively, at Week 12, which
were similar to the results of the present study (Table 3). Lower
response rates in the present study compared to the data of
Western countries might be attributed to the genetic difference,
patient characteristics (treatment failed with 2 systemic agents
plus phototherapy), and small sample size of the study group.
Despite these, patients still achieved satisfactory reduction in PASI
scores (reduction of 49.8% and 59.8% at Week 12 and Week 24,
respectively).
There are limited data to elucidate if patients with concurrent
PsA will interfere with the treatment effect of biological agents on
psoriasis. In the present study, the effect of etanercept on diseasebaseline in PASI 25, PASI 50, PASI 75, and PASI 90 scores atWeeks 12 and 24 between
Week 24
PASI 90 PASI 25 PASI 50 PASI 75 PASI 90
4.5 95.2 66.7 23.8 14.3
3.4 d 59 37 14
Table 5 Comparison of the mean PASI improvement between patients treated with and without concomitant topical medications during etanercept treatment.
Mean PASI improvement (%) at Week 12 PASI improvement (%) at Week 24
(A) With concomitant topical medication (n ¼ 14), % 48.2 53.3
(B) Without concomitant topical medication (n ¼ 8), % 51.6 68.5
(C) Total (n ¼ 22), % 49.8 59.8
Value of p for (A) and (B)* 0.0002 <0.0001
* Signiﬁcant at p < 0.05.
PASI ¼ Psoriasis Area and Severity Index.
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(p ¼ 0.94 at Week 12 and p ¼ 0.90 at Week 24) (Table 4).
Topical medications including topical corticosteroid, vitamin D3
analogs, and anthralin had been used as adjunctive therapies in
patients receiving etanercept for psoriasis treatment.18,19 In the
present study, all patients did not receive systemic medication or
phototherapy as a concomitant treatment. Topical medications
(e.g., coal tar, topical steroid, or vitamin D3 analogs) were
prescribed in 14 (63.6%) patients on their request or due to poorer
disease control. In patients treated with concomitant topical
medications, the PASI improvement at Week 12 and Week 24 was
48.2% and 53.3%, respectively, which showed worse disease control
compared to the groups using etanercept as a monotherapy
(p ¼ 0.0002 at Week 12 and p < 0.0001 at Week 24) (Table 5). This
result may be attributed to the fact that patients with poor psoriasis
control needed more therapeutic options.
One analysis of three clinical trials using etanercept as a mono-
therapy in treating psoriasis demonstrated its safety.7 By Week 12,
the most common adverse event was upper respiratory infection
(9.5%), followed by headache (8.9%) and injection site ecchymosis
(6.4%) in the group with etanercept 50 mg BIW. Percentages of
serious adverse events and serious infections were estimated to be
1.1% and 0.3%, respectively. In the current study, 10 (45.5%) patients
had upper respiratory infection by Week 12, while no headache or
injection site injury occurred. No serious adverse event or infection
was noted.
In a retrospective analysis of 17 patients with concurrent
psoriasis and HBV or hepatitis C, who were treated with anti-TNF-
a agents, there was no abnormal liver function or increased viral
load.20 The HBV carrier in the present study also showed no sign of
viral reaction.
Inﬂammatory markers for psoriasis had previously been
surveyed in one study that enrolled 41 patients treated with eta-
nercept 50 mg BIW. ESR, high-sensitivity CRP, and other markers
were measured at baseline and Week 12.12 By Week 12, all
inﬂammatory markers were reduced (p < 0.001). Interestingly,
better improvement of high-sensitivity CRP and ESR was correlated
with more PASI 75 responses. All patients in the present study
showed reduction of ESR and CRP by Week 12. Furthermore, there
was no correlation between PASI 75 achievement and reduced rates
of ESR and CRP.
A retrospective, observational study by Pink et al13 elucidated
that 16.7% of psoriasis patients developed positive ANA titers on
their ﬁrst treatment with anti-TNF-a agents. When patients failed
to respond with more than one anti-TNF-a agent, the possibility of
ANA development might increase. In the current study, no patient
received anti-TNF treatment previously. Four (18.2%) patients
developed positive ANA and one of them (25.0%) had worse
psoriasis control. TNF-a antagonist-induced lupus-like syndrome
with the induction of autoantibodies is reportedly more commonly
associatedwith etanercept and inﬂiximab.21 None of the patients in
this study had lupus-like syndrome during the treatment course.
Several reports have shown that serum TNF-a level may
increase after using etanercept for the treatment of diseases other
than psoriasis.14e17 Although there is more detectable TNF-a inblood, it is not active biologically or immunologically. However,
TNF-mediated diseases may occasionally be induced.14,22e24 In the
present study, 15 of 16 (93.8%) patients had increased serum TNF-
a levels at Week 12. Nonetheless, the clinical response (PASI
improvement) is not associated with the change in TNF-a level
(R2 ¼ 0.096 and p ¼ 0.72). Furthermore, diseases commonly asso-
ciated with increased TNF level, such as rheumatoid arthritis,
ankylosing spondylitis, inﬂammatory bowel disease, or heart
failure, did not occur in the study patients. Longer follow-up of
serum TNF-a level after Week 12 was not complete due to poor
patient compliance for blood test and discontinuation of etanercept
therapy after 24 weeks. Further large-scale, long-term studies are
needed to establish a more comprehensive analysis of the rela-
tionships between serum TNF-a level and psoriasis control.
In conclusion, clinical use of etanercept is effective and safe in
Asian patients to treat recalcitrant psoriasis. It can reduce serum
levels of inﬂammatory markers, including ESR and CRP, and occa-
sionally induces positive ANA titers with associated treatment
failure. Serum TNF-a level may increase after etanercept treatment
but does not seem to inﬂuence the PASI improvement.References
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